|[March 18, 2014]
Research and Markets: US Personalized Cancer Genome Sequencing Market Outlook 2018 Report Out Now
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/xrf9nw/us_personalized)
has announced the addition of the "US
Personalized Cancer Genome Sequencing Market Outlook 2018"
report to their offering.
The whole genome sequencing technology, over the past decade, has
developed at an unprecedented rate. There has been a rapid progression
from targeted gene sequencing to targeted whole genome sequencing
coupled with bioinformatics based sequencing platforms to analyze the
data and thereby impart personalized treatment to individuals. The Whole
Genome Sequencing has proved to be a key to new breakthrough in fighting
against cancer. The explosion of genomic data into personalized
treatment of cancer is due to the development of new methods, and the
exponential decline in cost of whole genome sequencing.
The report entitled US Personalized Cancer Genome Sequencing Market
Outlook 2018 entails detailed study of current and future cancer
prevalence and incidences across US. In addition, it provides an insight
about the leading states with cancer incidences. Also covered is age
wise statistics for cancer and comprehensive figures for cancer in males
and females. Further, we have provided potential states for whole genome
sequencing to help market players gauge maximum opportunity for growth.
Besides, the report also provides potential customer base and the
market's growth potential for personalized cancer WGS till 2018.
The said advanced technology has potential to revolutionize the field of
medicine. The author has closely monitored the regulatory landscape
related to sequencing which requires consideration of the authorities
over genome based tests. It has been observed that whole genome
sequencing services have been concurrently regulated by FDA, CDC and
CMS. Further, the author has also discussed the various constraints
faced by the industry players with suitable suggestions to overcome
them. Apart from this, a major hurdle is to persuade health insurers to
reimburse for the cost of sequencing the genomes of individual.
-Beckman Coulter Genomics
-BGI Americas Corporation
For more information visit http://www.researchandmarkets.com/research/xrf9nw/us_personalized
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To TMCnet.com's Homepage ]